Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of “Hold” from Brokerages

Neumora Therapeutics, Inc. (NASDAQ:NMRA) has received a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the firm, MarketBeat.com reports. Three analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.1429.

A number of research firms have weighed in on NMRA. Stifel Nicolaus lifted their target price on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a report on Monday, November 17th. Needham & Company LLC raised their price objective on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Tuesday, October 28th. Royal Bank Of Canada raised shares of Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and boosted their price objective for the company from $4.00 to $7.00 in a research note on Monday, December 1st. Guggenheim upgraded shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Monday, October 27th. Finally, JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from a “neutral” rating to an “underweight” rating in a report on Tuesday, September 16th.

Insider Activity at Neumora Therapeutics

In other Neumora Therapeutics news, Director Kristina Burow purchased 1,915,700 shares of the stock in a transaction on Monday, October 27th. The shares were purchased at an average price of $2.61 per share, with a total value of $4,999,977.00. Following the acquisition, the director directly owned 6,046,907 shares in the company, valued at approximately $15,782,427.27. The trade was a 46.37% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Daljit Singh Aurora sold 114,703 shares of the business’s stock in a transaction dated Tuesday, November 11th. The stock was sold at an average price of $2.68, for a total value of $307,404.04. The disclosure for this sale is available in the SEC filing. 26.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of NMRA. AlphaCore Capital LLC bought a new position in shares of Neumora Therapeutics in the 2nd quarter worth $248,000. Catalyst Funds Management Pty Ltd purchased a new position in Neumora Therapeutics in the second quarter worth $29,000. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Neumora Therapeutics in the second quarter valued at $41,000. Y Intercept Hong Kong Ltd bought a new position in Neumora Therapeutics in the second quarter valued at $42,000. Finally, Savant Capital LLC purchased a new stake in Neumora Therapeutics during the second quarter valued at about $52,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Trading Down 4.7%

Shares of NMRA stock opened at $2.22 on Monday. The stock has a market capitalization of $370.94 million, a price-to-earnings ratio of -1.51 and a beta of 3.22. The company’s fifty day simple moving average is $2.20 and its two-hundred day simple moving average is $1.88. Neumora Therapeutics has a 1 year low of $0.61 and a 1 year high of $3.25. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.85 and a quick ratio of 6.85.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). As a group, analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.